Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Recruiting 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 1Breast 1

Conditions

Ovarian Neoplasms 1Fallopian Tube Neoplasms 1Endometrial Neoplasms 1Breast Neoplasms 1

Interventions

Specimen Handling 465Magnetic Resonance Spectroscopy 351pembrolizumab 297Biopsy 251Carboplatin 235Cisplatin 199Cyclophosphamide 191Paclitaxel 167Nivolumab 159Gemcitabine 154Radiotherapy 129Bevacizumab 128Dexamethasone 115fludarabine 103Pemetrexed 102Fluorouracil 96Radiation 94Doxorubicin 94atezolizumab 93Docetaxel 93durvalumab 92venetoclax 91Rituximab 89Oxaliplatin 89Leucovorin 82Capecitabine 79Prednisone 78Lenalidomide 72X-Rays 69Etoposide 69

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Biosimilar Pharmaceuticals × 30 days × Clear all
NCT03564340 2026-05-08

Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers

Regeneron Pharmaceuticals

Phase 1/2 Recruiting
890 enrolled
Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms, Endometrial Neoplasms

NCT07220135 2026-05-06

NeoTHERa

University of Kansas Medical Center

Phase 2 Recruiting
100 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡